Seer (SEER) Net Income towards Common Stockholders (2020 - 2026)
Seer (SEER) posted quarterly Net Income towards Common Stockholders of -$16.8 million for Q1 2026, up 15.6% year-over-year from -$14.6 million in Q1 2025, and down 5.27% quarter-over-quarter from -$16.0 million in Q4 2025.
Analysis
Seer (SEER) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Seer's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$16.8 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 15.6% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$70.5 million (up 18.15% YoY), while the FY2025 annual figure was -$73.6 million, up 15.25% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$16.8 million, down from -$16.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$16.0 million in Q4 2025, with the low at -$66.0 million in Q1 2022.
- The 5-year median for Net Income towards Common Stockholders is -$22.0 million (2024), against an average of -$29.1 million.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders tumbled 260.17% in 2022, then soared 67.48% in 2024.
- Seer's Net Income towards Common Stockholders stood at -$22.5 million in 2022, then increased by 17.86% to -$18.5 million in 2023, then retreated by 18.85% to -$22.0 million in 2024, then advanced by 27.27% to -$16.0 million in 2025, then slipped by 5.27% to -$16.8 million in 2026.
- Business Quant data shows SEER's Net Income towards Common Stockholders at -$16.8 million in Q1 2026, -$16.0 million in Q4 2025, and -$18.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Seer | 107.57 Mn | 107.57 Mn | 1.51 Mn | -16.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.90 Mn |
| Mar 31, 2026 | -16.84 Mn |
| Dec 31, 2025 | -379,000.00 |
| Sep 30, 2025 | -18.23 Mn |
| Jun 30, 2025 | -19.42 Mn |
| Mar 31, 2025 | -19.95 Mn |
| Dec 31, 2024 | -3.48 Mn |
| Sep 30, 2024 | -21.33 Mn |
| Jun 30, 2024 | -22.85 Mn |
| Mar 31, 2024 | -20.68 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Sep 30, 2023 | -21.09 Mn |
| Jun 30, 2023 | -23.43 Mn |
| Mar 31, 2023 | -23.96 Mn |
| Dec 31, 2022 | -22.53 Mn |
| Sep 30, 2022 | -23.98 Mn |
| Jun 30, 2022 | -22.82 Mn |
| Mar 31, 2022 | -23.65 Mn |
| Dec 31, 2021 | -19.74 Mn |
| Sep 30, 2021 | -18.39 Mn |